Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 21Esophageal Squamous Cell Carcinoma 19Esophageal Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Hodgkin Disease 6Cholangiocarcinoma 6Liver Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Advanced Solid Tumor 4Advanced Gastric Cancer 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

Doxorubicin 3lentiviral minigene vaccine of COVID-19 coronavirus 1eltrombopag 1camrelizumab 1apatinib 1Vinorelbine 1Trabectedin 1Temozolomide 1Sodium Chloride 1Methotrexate 1Irinotecan 1FANG vaccine 1Dexamethasone 1Cisplatin 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Connective and Soft Tissue × camrelizumab × Clear all
NCT04910126 2021-06-02

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
84 enrolled
Sarcoma

Sarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡